Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor


Wyświetlanie 1-9 z 9
Tytuł :
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Autorzy :
Hannani D
Vétizou M
Enot D
Rusakiewicz S
Chaput N
Klatzmann D
Desbois M
Jacquelot N
Vimond N
Chouaib S
Mateus C
Allison JP
Ribas A
Wolchok JD
Yuan J
Wong P
Postow M
Mackiewicz A
Mackiewicz J
Schadendorff D
Jaeger D
Korman AJ
Bahjat K
Maio M
Calabro L
Teng MW
Smyth MJ
Eggermont A
Robert C
Kroemer G
Zitvogel L
Pokaż więcej
Źródło :
Cell research [Cell Res] 2015 Mar; Vol. 25 (3), pp. 399-400.
Typ publikacji :
Published Erratum
Tytuł :
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Autorzy :
Hannani D; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Vétizou M; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Enot D; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U848, Villejuif, France [3] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France.
Rusakiewicz S; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Chaput N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Klatzmann D; 1] INSERM, Unité Mixte de Recherche_S959, I, Paris, France [2] Assistance-Publique Hopitaux de Paris, Hôpital Pitié-Salpêtrière, Biotherapy, Paris, France.
Desbois M; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Jacquelot N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Vimond N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Chouaib S; INSERM U753, Villejuif, France.
Mateus C; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] Department of Medical Oncology, IGR, Villejuif, France.
Allison JP; Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
Ribas A; University of California Los Angeles, Los Angeles, CA, USA.
Wolchok JD; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yuan J; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Wong P; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Postow M; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Mackiewicz A; 1] Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland [2] Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Mackiewicz J; 1] Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland [2] Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Schadendorff D; Department of Dermatology, University Hospital Essen, Germany.
Jaeger D; National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
Zörnig I
Hassel J
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, USA.
Bahjat K; Earle A Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Maio M; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Calabro L; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Teng MW; 1] QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia [2] School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia.
Smyth MJ; 1] QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia [2] School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia.
Eggermont A; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] INSERM U981, Villejuif, France.
Robert C; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Department of Medical Oncology, IGR, Villejuif, France [4] INSERM U981, Villejuif, France.
Kroemer G; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U848, Villejuif, France [3] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France [4] Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France [6] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Zitvogel L; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France [4] Department of Medical Oncology, IGR, Villejuif, France.
Pokaż więcej
Źródło :
Cell research [Cell Res] 2015 Feb; Vol. 25 (2), pp. 208-24. Date of Electronic Publication: 2015 Jan 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*metabolism
Interleukin-2 Receptor alpha Subunit/*blood
Melanoma/*pathology
Receptors, Interleukin-2/*metabolism
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CTLA-4 Antigen/immunology ; Cohort Studies ; Disease Models, Animal ; Female ; Humans ; Immunotherapy ; Interleukin-2 Receptor alpha Subunit/immunology ; Ipilimumab ; Male ; Melanoma/mortality ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Receptors, Interleukin-2/genetics ; Receptors, Interleukin-2/immunology ; Recombinant Proteins/biosynthesis ; Recombinant Proteins/genetics ; Recombinant Proteins/pharmacology ; T-Lymphocytes, Regulatory/immunology ; Up-Regulation/drug effects ; Young Adult
Czasopismo naukowe
    Wyświetlanie 1-9 z 9

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies